Lianne T Philhower
Biographic Data
| ID | 1845453 |
|---|---|
| NAME | Lianne T Philhower |
| GIVEN NAMES | Lianne T |
| FAMILY NAME | Philhower |
| SIGNATURE | PHILHOWER L T |
| AFFILIATIONS | Chaminade University of Honolulu |
| VERIFIED | No |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2023 |
| LATEST PUBLICATION YEAR | 2024 |
| H-INDEX | 0 |
MDMA-assisted dialectical behavioral therapy for borderline personality disorder
In 2021, the final series of phase 3 clinical trials looking at MDMA-AT for treatment-resistant post-traumatic stress disorder (PTSD) found that 71.2% of 3,4-methylenedioxymethamphetamine (MDMA) full-dose participants no longer met criteria for PTSD. MDMA-assisted therapy is not US Food and Drug Administration (FDA) approved in treating borderline personality disorder (BPD), and while PTSD is quite different from BPD, it is possible that some of …
MDMA-assisted therapy for borderline personality disorder
Associated with high-risk behavior, borderline personality disorder (BPD) remains one of the field's most misunderstood, misdiagnosed, and stigmatized conditions. Individuals with BPD are frequently labeled as treatment-resistant patients. Furthermore, 25-58% of BPD individuals have a comorbid diagnosis of post-traumatic stress disorder (PTSD), and BPD may be conceptualized as a trauma-spectrum disorder. In Phase 3 clinical trials for 3,4-methyle…
No prominent works on this page.
MDMA-assisted therapy for borderline personality disorder
Associated with high-risk behavior, borderline personality disorder (BPD) remains one of the field's most misunderstood, misdiagnosed, and stigmatized conditions. Individuals with BPD are frequently labeled as treatment-resistant patients. Furthermore, 25-58% of BPD individuals have a comorbid diagnosis of post-traumatic stress disorder (PTSD), and BPD may be conceptualized as a trauma-spectrum disorder. In Phase 3 clinical trials for 3,4-methyle…
MDMA-assisted dialectical behavioral therapy for borderline personality disorder
In 2021, the final series of phase 3 clinical trials looking at MDMA-AT for treatment-resistant post-traumatic stress disorder (PTSD) found that 71.2% of 3,4-methylenedioxymethamphetamine (MDMA) full-dose participants no longer met criteria for PTSD. MDMA-assisted therapy is not US Food and Drug Administration (FDA) approved in treating borderline personality disorder (BPD), and while PTSD is quite different from BPD, it is possible that some of …
Borderline personality disorder (2 works) · Clinical Psychology (2 works) · Dialectical Behavior Therapy (2 works) · MDMA (2 works) · Psychedelics and Drug Studies (2 works) · Psychiatry (2 works) · Psychology (2 works) · Psychotherapist (2 works) · Psychotherapy Techniques and Applications (2 works) · Behavioral therapy (1 work)